The Republic of Malta and endoscopic eradication therapy for Barrett’s esophagus

• References

• 1 Pandey G, Mulla M, Lewis WG. et al. Systematic review and meta-analysis of the effectiveness of radiofrequency ablation in low grade dysplastic Barrett's esophagus. Endoscopy 2018; 50: 953-960
• 2 Guthikonda A, Cotton CC, Madanick RD. et al. Clinical outcomes following recurrence of intestinal metaplasia after successful treatment of Barrett's esophagus with radiofrequency ablation. Am J Gastroenterol 2017; 112: 87-94
• 3 Haidry RJ, Dunn JM, Butt MA. et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma: Outcomes of the UK national Halo RFA registry. Gastroenterology 2013; 145: 87-95
• 4 Komanduri S, Kahrilas PJ, Krishnan K. et al. Recurrence of Barrett's esophagus is rare following endoscopic eradication therapy coupled with effective reflux control. Am J Gastroenterol 2017; 112: 556-566
• 5 Orman ES, Kim HP, Bulsiewicz WJ. et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation. Am J Gastroenterol 2013; 108: 187-195
• 6 Phoa KN, van Vilsteren FG, Weusten BL. et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: A randomized clinical trial. JAMA 2014; 311: 1209-1217
• 7 Shaheen NJ, Sharma P, Overholt BF. et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. NEJM 2009; 360: 2277-2288
• 8 Sharma VK, Jae KimH, Das A. et al. Circumferential and focal ablation of Barrett's esophagus containing dysplasia. Am J Gastroenterol 2009; 104: 310-317
• 9 Small AJ, Araujo JL, Leggett CL. et al. Radiofrequency ablation is associated with decreased neoplastic progression in patients with Barrett's esophagus and confirmed low-grade dysplasia. Gastroenterology 2015; 149: 567-576 e563
• 10 Shaheen NJ, Falk GW, Iyer PG. et al. ACG clinical guideline: Diagnosis and management of Barrett's esophagus. Am J Gastroenterol 2016; 111: 30-50
• 11 Weusten B, Bisschops R, Coron E. et al. Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy 2017; 49: 191-198
• 12 Vennalaganti PR, Kaul V, Wang KK. et al. Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: A multicenter, prospective, randomized trial. Gastrointest Endosc 2018; 87: 348-355
• 13 Bartel MJ, Srivastava A, Gordon S. et al. Subsquamous intestinal metaplasia is common in treatment-naive Barrett's esophagus. Gastrointest Endosc 2018; 87: 67-74
• 14 Trindade AJ, Inamdar S, Smith MS. et al. Volumetric laser endomicroscopy in Barrett's esophagus: Interobserver agreement for interpretation of Barrett's esophagus and associated neoplasia among high-frequency users. Gastrointest Endosc 2017; 86: 133-139
• 15 Komanduri S, Muthusamy VR, Wani S. Controversies in endoscopic eradication therapy for Barrett's esophagus. Gastroenterology 2018; 154: 1861-1875 e1861
• 16 Phoa KN, Rosmolen WD, Weusten B. et al. The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: Results from a randomized controlled trial (SURF trial). Gastrointest Endosc 2017; 86: 120-129 e122
• 17 Quante M, Graham TA, Jansen M. Insights into the pathophysiology of esophageal adenocarcinoma. Gastroenterology 2018; 154: 406-420
• 18 Imperiale TF, Ransohoff DF, Itzkowitz SH. et al. Multitarget stool DNA testing for colorectal-cancer screening. NEJM 2014; 370: 1287-1297
• 19 Iyer PG, Taylor WR, Johnson ML. et al. Highly discriminant methylated DNA markers for the non-endoscopic detection of Barrett's esophagus. Am J Gastroenterol